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ABSTRACT
Objective: To discuss issues in the design of a measurement
strategy related to the use of patient-reported outcomes
(PROs) in support of a labelling claim.
Methods: In association with the release by the US Food and
Drug Administration of its draft guidance on the use of PROs
to support labeling claims, the Mayo/FDA Patient-Reported
Outcomes Consensus Writing Group was formed. This
paper, part of a series of manuscripts produced by the
Writing Group, focuses on designing a PRO measurement
strategy.
Results: Developing a PRO measurement strategy begins
with a clear statement about the proposed label claim that
will derive from the PRO data. Investigators should identify
the relevant domains to measure, develop a conceptual
framework, identify alternative approaches for measuring the
domains, and synthesize the information to design the mea-
surement strategy.
Often, there is not an already existing single instrument
that has been developed and validated for the purposes of a
given study. In such cases, investigators may consider supple-
menting an already existing questionnaire with additional
scales or questions, modifying already existing instruments
for a new application or patient population, or developing a
new instrument altogether. The level of revalidation required
for modiﬁcations and adaptations depends on the extent of
the changes made. Revalidation requirements may range
from cognitive testing/debrieﬁng to conﬁrm that subjects
respond to the new instrument as expected to full-scale reli-
ability and validity evaluations.
Conclusion: A position of “reasonable pragmatism” is rec-
ommended such that the best available measurement strategy
be considered as evidence for labeling.
Keywords: instrument selection, patient-reported outcomes,
validation.
Introduction
Many therapeutics carry the potential to beneﬁt
people in ways that are best measured by self-report,
commonly referred to as patient-reported outcomes
(PROs). The US Food and Drug Administration (FDA)
released a draft guidance document regarding the
incorporation of PROs in the regulatory context of
drug development and approval [1]. In this article, we
discuss topics related to instrument selection or, more
generally, to designing a PRO measurement strategy
including issues directly and indirectly related to the
guidance document.
In a regulatory context, an outcome measurement
strategy begins with a clear statement about the pro-
posed label claim that will derive from the PRO data.
The proposed label claim sets the objectives for PRO
measurement and guides the design of the measure-
ment strategy. In the meeting pertaining to the guid-
ance document, the FDA stressed that “claims contain
concepts,” with the concept being the thing or event to
be measured. Thus, “success depends on alignment of
product development, PRO development, and clinical
trial objectives” [2].
Thus, the measurement strategy should reﬂect a
conceptual framework that represents the hypoth-
esized relationships across the PRO domains of inter-
est [3]. The measurement strategy is the operational
realization of the conceptual framework through items
or instruments designed to assess the domains of inter-
est. The proposed claim will likely use language that is
more or less synchronous with language and concepts
in any number of candidate PRO instruments that
have been validated or are being validated.
A single “perfect” instrument to measure the PROs
targeted by the proposed label claim may not exist.
Rather than simply selecting an instrument “off the
shelf,” researchers often need to design a defensible
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measurement strategy from available approximations
to get the perfect instrument. This measurement strat-
egy may involve combining previously developed and
validated instruments in ways they have been used
before, modifying or adapting already existing instru-
ments for a new purpose, or even developing new
questions or instruments.
Setting Goals and Framing the Context for
PRO Measurement
The conceptual framework guides the PRO measure-
ment strategy, but the strategy need not be fully
exhaustive of the framework. Goals may vary from
providing a comprehensive proﬁle of the impact on
health-related quality of life, to focusing on the impact
on speciﬁc domains of health-related quality of life, or
to investigating other PROs such as treatment satisfac-
tion or patient bother. The scope of the goal relates to
the proposed label claim and the concepts in that claim
within the conceptual framework.
A PRO claim may encompass an important disease
outcome (e.g., a common or disabling symptom) or an
important treatment outcome (e.g., reduction in usual
side effects observed in standard therapies), and it
should include a justiﬁcation for their importance.
Temple has deﬁned a clinically meaningful outcome in
the context of drug development as “. . . a direct
measure of how a patient feels, functions, or survives
and is expected to predict the effect of therapy” [4].
The nature of the PRO measure will concern a disease,
condition or health state, a population, and a treat-
ment. The effect or outcome will relate to changes in
function and in clinical course that correspond to
variations in the test results [5].
The importance of the differences in clinical out-
comes between treated and control patients will be
gauged by the magnitude of the result [6]. A labeling
claim could be targeted at single or multiple speciﬁc
domains (e.g., decreased fatigue in anemia patients or
improved vitality in other patients), single or multiple
general functioning domains (e.g., physical function
and social function in anemia patients), or summary of
overall scores (e.g., the Physical Component Summary
of the SF-36). The major point is that the claim should
focus on an a priori hypothesis of improvement that
the data can support.
Investigators should develop and evaluate their
PRO measurement strategy and research plan similar
to how they devise their clinical end point measure-
ment strategy and research plan. Considerations
include biological plausibility; prior clinical research
data; evidence of methodological development; clinical
perceptions of use, effect, and meaning; knowledge
of feasibility in a research setting; understanding of
public health consequences; and patients’ views con-
cerning importance and meaning [7]. With both PRO
end points and clinical end points, “all claims of clini-
cal beneﬁt require substantial evidence” supported by
adequate and well-controlled evaluations (i.e., having
adequate development and appropriate research
design and statistics including a prespeciﬁed analysis
plan) [8]. These requirements apply regardless of
whether the goals of the PRO measurement strategy
are broad or narrow, unidimensional or multidimen-
sional, single-item or multi-item. The key point is that
the PRO measurement strategy should be designed
based on the goals of PRO measurement as outlined in
the target claim. The well-controlled research design
affords an opportunity to test a PRO measurement
strategy, and similar to clinical research, not all PRO
concepts need to be tested in the same research
program.
The PRO measurement strategy should be designed
and evaluated similarly to the broader clinical mea-
surement strategy by being appropriate both for
comparable rigor and for comparable reason and
pragmatism. If, using the above example of fatigue and
anemia, sponsors and regulators agree that fatigue is
an important PRO to document in a drug registration
program, then the “best available measurement” of
fatigue should be accepted in submission of data. More
than one “best available” instrument or instruments to
use for PRO measurement may exist.
The measurement approach, if well-documented,
would logically be acceptable in the labeling claim,
even if every component of the background conceptual
framework or measurement strategy is not fully satis-
ﬁed. Such an approach would represent a “level
playing ﬁeld” for PRO and clinical outcome data, as
the latter are often equally or even more imprecise
(lacking reliability) than PRO data [9].
A position of “reasonable pragmatism” would
allow for the best available measurement to be con-
sidered as evidence for labeling. If done in such a way
that promotes further development of the conceptual
and measurement frameworks, this practice would
truly advance the ﬁeld. Because the review and accep-
tance of frameworks and their proposed measurement
is highly subjective, to do otherwise risks deeming
PRO data as inadequate for consideration based
on individual preferences for frameworks and their
measurement.
Developing the Measurement Strategy
Investigators can take the following steps to design a
PRO measurement strategy: 1) identify the relevant
domains to measure; 2) develop a conceptual frame-
work; 3) identify alternative approaches for measuring
the domains; and 4) synthesize the information to
design the measurement strategy. These steps represent
the process that a company could go through to
develop its PRO measurement strategy. The FDA
spoke strongly in favor of sponsors providing complete
and detailed documentation describing the develop-
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ment of any PRO instrument used to support a claim
[2]. Nevertheless, an argument can be made for the
FDA’s receiving only complete information about the
claim and the instrument(s) used to support that claim
related to the domains to be studied. The necessity of
providing a comprehensive listing of every domain
affected by the disease and its treatment, or a compre-
hensive description of alternatives for measuring every
domain, adds signiﬁcantly to cost and documentation
required in the claims submission.
Step 1: Identifying the relevant domains to measure.
In determining the relevant domains to measure, inves-
tigators should develop a comprehensive list of
domains that are affected by the disease itself and also
its treatments based on their therapeutic effects and
side effects. Next, using all available information, they
should create a list of the domains that are expected to
be affected by the experimental therapy. In each case,
consideration must be given to both positive and nega-
tive effects. Then they should narrow the list based on
relevance criteria, in particular whether the domain is
relevant to the proposed labeling claim.
Regarding the negative impact of therapy, both
experimental and control, side effects are often
assessed through the provider-completed adverse event
reporting system (e.g., using a Common Toxicity Cri-
teria scoring system). This is not PRO measurement as
considered in this article. In some cases, investigators
may wish to assess these side effects as part of the PRO
measurement strategy. They may want to obtain infor-
mation on the functional impact of the side effect, such
as conducting an assessment of the bother of (rather
than the frequency or severity of) certain side effects.
Because adverse events and PROs are not synony-
mous, both have a place in assessing the impact of
therapy. Because standard adverse event reporting may
fail to detect some differences, PROs may provide a
more sensitive measure in some instances. When a
sponsor wishes to demonstrate a superior safety proﬁle
(i.e., fewer or less severe side effects), getting the infor-
mation directly from the patient is well-advised,
although not mandatory. Thus, although a sponsor
may choose at times to assess the negative effects
through its PRO measurement strategy, PRO assess-
ment of negative aspects of treatment should not be
confused with standard assessment of adverse drug
events [10].
Step 2: Development of a conceptual framework. The
next step is to develop a conceptual framework based
on the identiﬁed domains. The conceptual framework
should outline the relationship between the domains
and the hypothesized impacts, both positive and nega-
tive, of the experimental and control therapies. This
conceptual framework may be useful in reﬁning the
goals for PRO measurement. Speciﬁcally, investigators
can use the conceptual framework to identify their
ﬁnal domains of interest and set priorities for the truly
important ones––i.e., those for which the company
aims to obtain a labeling claim and thus those that will
be most important in designing the PRO measurement
strategy. For companies that also seek to conduct a
more comprehensive PRO measurement as part of the
study, the conceptual framework can help identify all
of the domains of interest, not just those that will be
used to support the labeling claim. For more informa-
tion on developing a conceptual framework, see the
article by Rothman et al. [3].
Step 3: Identifying candidate approaches for mea-
suring the domains. After investigators identify the
relevant domains and develop a conceptual frame-
work, their next step is to identify the most suitable
approach for measuring the domains of interest from
alternative approaches. Not uncommon is a situation
in which no single instrument covers all domains tar-
geted for the labeling claim. In such instances, investi-
gators may need to use multiple instruments, to modify
or adapt an existing instrument, or to develop a com-
pletely new instrument. Thus, determining how to
measure a PRO in a regulatory context involves not
simply selecting an instrument, but rather designing a
measurement strategy that will address the targeted
domains.
Researchers should consider the relative strengths
and weaknesses of the alternative instruments in terms
of their comprehensiveness and their psychometric per-
formance [11]. The Medical Outcomes Trust (MOT)
developed a list of review criteria that can be used to
evaluate the performance of candidate measures [12].
The eight review criteria theMOT proposes include the
conceptual and measurement model, reliability, valid-
ity, responsiveness, interpretability, burden of adminis-
tration, alternative forms/modes of administration,
and cultural and language adaptations. For more infor-
mation on evaluating the psychometric performance
of instruments, see the article by Frost et al. [13].
When considering alternative measurement ap-
proaches, one should ﬁrst determine whether an exist-
ing single instrument is an option. The literature
should be searched to identify which instruments have
been used previously in similar studies to determine
how well they performed. The literature may contain
potentially useful instruments that have not been used
previously in similar studies. An example of the use
of a single instrument occurred in the evaluation of
Advair Diskus (GlaxoSmithKline, Research Triangle
Park, NC, USA) for patients with asthma. The Asthma
Quality of Life Questionnaire (AQLQ) was used to
assess the patient’s perception of asthma and its treat-
ment. Based on the AQLQ results, the label for Advair
notes that patients in the Advair Diskus group experi-
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enced improvements in their overall asthma-speciﬁc
quality of life that were clinically meaningful in com-
parison with the group on placebo [14].
An existing single instrument for the targeted
domains may not be available or sufﬁcient, in which
case alternative approaches to PRO measurement
should be considered. Although the FDA draft guid-
ance states that if an adequate PRO instrument does
not exist a new PRO instrument can be developed [1],
investigators have several alternative options when an
existing instrument is not adequate. They may be able
to modify or adapt existing instruments. Also, if an
instrument covers most of the domains of interest, it
can be used and supplemented with scales or items
from other existing instruments or even with scales
that are developed for that particular study. Such adap-
tations and modiﬁcations require varying degrees of
revalidation work as discussed in the second half of
this article.
The evaluation of etanercept for rheumatoid arthri-
tis (RA) illustrates a measurement strategy using mul-
tiple instruments to cover the relevant domains. Several
PRO measures were used, including the Health Assess-
ment Questionnaire (HAQ), the SF-36, items assessing
energy and mental health from the Medical Outcomes
Study, and a single-item rating scale assessing current
health [15]. The resulting package insert notes that all
subdomains of the HAQ improved in patients receiving
etanercept in two studies. It also notes that, in the study
that included the SF-36, the patients receiving 25 mg
etanercept showed signiﬁcantly more improvement in
the SF-36 physical component summary than the
patients receiving 10 mg etanercept [16].
Another option when no single existing instrument
addresses the relevant domains is to modify or adapt an
instrument previously used in other studies and tailor it
to the objectives of the proposed study. For example,
eﬂornithine cream was developed to treat unwanted
facial hair (hirsutism), but no existing PRO instrument
assessed the impact of hirsutism. In this case, the
researchers developed the ESTEEM scale (Exchanges of
affection, Social interactions, Time spent removing
facial hair, Encountering new people, Engaging in work
or school, Minimizing overall bother with facial hair)
by adapting the Bother Assessment in Skin Conditions
scale (BASC), that had been developed and validated in
the assessment of hyperpigmentation. The BASC was
modiﬁed to create the ESTEEM scale by adapting char-
acteristics of bother and discomfort to the setting of
hirsutism [17]. The resulting label claim for eﬂornithine
notes that it signiﬁcantly reduced how bothered
patients felt by their facial hair and by the time spent
removing, treating, or concealing facial hair [18].
A ﬁnal alternative is to develop a new instrument
speciﬁcally tailored to the study. This approach, too,
requires documentation that the new instrument is
valid and reliable in this setting. For example, the
International Index of Erectile Function (IIEF) was
developed to detect changes resulting from treatment
for erectile dysfunction [19]. The IIEF was used as the
primary measure for the clinical efﬁcacy of sildenaﬁl,
speciﬁcally focusing on two questions related to ability
to achieve erections sufﬁcient for sexual intercourse and
maintenance of erections after penetration. Patients
also used daily diaries on their sexual function and
responded to a global question. Results from the IIEF
were used to support the labeling claim for sildenaﬁl,
which notes that maintenance of erections after pen-
etrationwas better in the sildenaﬁl-treated patients than
in placebo patients [20]. It also notes that sildenaﬁl
improved the frequency, ﬁrmness, and maintenance of
erections; frequency of orgasm; frequency and level of
desire; frequency, satisfaction, and enjoyment of inter-
course; and overall relationship satisfaction. For more
information on instrument development, see the article
by Turner et al. [21].
One ﬁnal consideration when evaluating alternative
measurement approaches is whether it is feasible and
advisable to include a general health status measure.
Adding a general health status measure can identify
unanticipated consequences, both positive and nega-
tive, of the experimental therapy or comparators.
Using such instruments can also promote comparisons
across diseases and populations. Including an addi-
tional instrument does increase administrative and
respondent burden and costs. Although investigators
should always consider this alternative, it will not
always be appropriate.
Step 4: Synthesizing the information to design the
measurement strategy. After identifying the relevant
domains and the alternative approaches for measuring
them, the research team needs to consider the trade-
offs of the various strengths and weaknesses and deter-
mine the best measurement strategy based on the
study’s priorities. First, they need to include domains
targeted for a labeling claim. Second, the instruments
used to measure the targeted domains should be psy-
chometrically sound, and the best available, for the
given application.
Patient-reported outcome researchers face trade-
offs when designing a measurement strategy. On the
one hand, using a previously developed and well-
validated instrument lends credibility to the measure-
ment strategy and allows for greater comparability
across studies. If the instrument does not adequately
target the relevant domains, it may not be as sensi-
tive and responsive in its measurement properties as
desired. On the other hand, using newly developed
questions that are speciﬁcally tailored to measure the
relevant outcomes for a given study may be more
sensitive to differences and responsive to changes, but
this approach requires signiﬁcantly more work to dem-
onstrate that the measure is valid and reliable.
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Using such study-speciﬁc instruments does not
promote cross-study comparisons. When investigators
must deal with such trade-offs, they may ﬁnd it helpful
to identify the domains of greatest importance and
ensure that those are measured with instruments of the
greatest validity and reliability and allow secondary
domains to be measured with instruments that may
not have been as well tested. For example, if a
company is targeting depression and sexual function
for a labeling claim but also wants to measure social
function and emotional well-being, depression and
sexual function should take priority in designing the
measurement strategy, with social function and emo-
tional well-being of secondary concern.
Because trade-offs and compromises will likely be
required, the next step is to consider how to strengthen
the weaker areas of the selected approach. If an instru-
ment is being supplemented with newly developed
items, pilot testing and validating these items before
their use may be helpful. Similarly, if a previously
developed and validated instrument is being used in
new ways or new populations, testing the instrument
in the target application or population before the main
study is the ideal practice. Validation concurrent with
the pivotal Phase III trial is a reasonable strategy, espe-
cially considering that the risk in this endeavor lies
with the sponsor.
In some circumstances, using pivotal Phase III data
to conﬁrm the psychometric properties of an instrument
is acceptable. For example, when a sponsor includes an
instrument in Phase II studies, analyzes its psychometric
properties, and on the basis of those analyses, revises
the instrument, it is reasonable and standard practice to
administer the revised version of the instrument in
phase III and use those data to conﬁrm the reliability
and validity of the ﬁnal version. The FDA is seemingly
still evaluating whether validation should be done
before Phase III trials. This approach may be incongru-
ous with the agency’s stance that, in certain circum-
stances, molecular biomarkers can be validated during
the course of pivotal Phase III trials. Ideally, in a con-
current validation strategy the data should be collected
parallel in time with a separate study.
Studies by Damiano et al. illustrate the four-step
process for designing a measurement strategy in prepa-
ration for clinical trials in Parkinson’s disease [11].
First, the researchers identiﬁed the areas affected by
Parkinson’s disease and its treatment. They conducted
a literature review and consulted with clinicians and
patients to identify the relevant domains. They also
identiﬁed the two Parkinson’s disease-speciﬁc ques-
tionnaires available at the time. They reviewed how
well the two Parkinson’s disease measures covered the
relevant domains and the evidence available regarding
their psychometric performance. Based on this review,
they developed and tested a measurement strategy in
the target population [22]. The measurement strategy
included one of the instruments evaluated in the re-
view (the Parkinson’s Disease Questionnaire-39), but
because this instrument did not address sexual func-
tion, they also included the MOS Sexual Function
Scale. Finally, the SF-36 was used to identify the
impact on general health status and to identify any
unanticipated consequences. They also used this vali-
dation study to evaluate two modes of administration
(at the study site and over the telephone). Thus, the
validation study could be used to support the applica-
tion of this measurement strategy in a clinical trial for
a regulatory submission.
A New Possibility
The best approach is often to use the best available
instrument and to make incremental changes to
improve its validity or relevance for the target study. In
the future, the selective use of large sets of questions
measuring key concepts (“item banks”) to create tai-
lored short forms has great appeal for regulatory use.
The tailored short forms might be static (i.e., the same
small set of items selected by the researcher in dis-
cussion with the FDA) or dynamic (i.e., computer-
adaptive tests, or CAT assessments). The advantage
of this approach is that the concept under discussion
has been well studied and the items in the instrument
comprising it have been calibrated to the underlying
concept being measured [23].
Through the National Institutes of Health PROMIS
network, groups of investigators are currently devel-
oping item banks to address pain, fatigue, and other
aspects of health-related quality of life (http://
www.nihpromis.org). As item banks are developed,
PRO researchers may have the opportunity to draw
from item banks using previously validated and cali-
brated items that can be targeted to the relevant out-
comes of interest.
Next, we discuss alternatives for modifying and
adapting PRO instruments in cases when an existing
questionnaire alone is inappropriate or insufﬁcient.
Special attention is given to the validation required for
such alternatives.
Requirements to Revalidate a Modiﬁed Instrument
Often no available instrument assesses the relevant
domains in the target population adequately, or exist-
ing assessment tools that are developed from the
general population or some disease population are not
easily transferable to the trial target population. Inves-
tigators face pressure to generate instruments that are
relevant to the domains of interest in the trial popula-
tion. Clinical trials are conducted under tight time-
lines, and developing a new instrument may not
always be feasible or even necessary. A viable option is
to modify and adapt existing instruments to ﬁt the
research needs. The types of modiﬁcations that may be
made include:
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• Changes in wording or content;
• Changes in mode of administration;
• Translation and cultural adaptation; and
• Application to a different patient population.
Modiﬁcations may occur as part of the natural evo-
lution of instruments, and as long as an investigator
or sponsor characterizes a viable PRO measurement
strategy in a methodologically sound manner, iterative
adaptations and modiﬁcations are acceptable. Modify-
ing and adapting existing instruments to ﬁt the
research needs is an acceptable approach as long as
four main conditions hold:
1. The existing instrument has been adequately vali-
dated; measurement properties have been estab-
lished, albeit for a different application (the
advantage of adapting an instrument over devel-
oping one de novo).
2. Questions in the adapted instrument are relevant
and appropriate for the target application.
3. The instrument is implementable; that is, it is logis-
tically able to be utilized in the particular setting.
4. A new interpretation guideline is developed if
necessary.
Alternative positions on the extent to which an
instrument’s psychometric properties need to be re-
evaluated after the instrument has been modiﬁed
range considerably. For simplicity, this re-evaluation
will be referred to as “revalidation.” The range of
positions includes the following:
1. All changes excepting superﬁcial (cosmetic)
changes require comprehensive revalidation,
including use of conﬁrmatory factor analysis for a
multidomain questionnaire. The psychometric
properties of the ﬁnal instrument must be estab-
lished before phase III.
2. Conﬁrming the basic psychometric properties of
the revised instrument in phase III trials is sufﬁ-
cient. The sponsor bears the risk if questionnaire
performance is inadequate. No other revalidation
is required.
3. Focus groups or individual patient interviews are
required to conﬁrm content validity. If content
validity is conﬁrmed, no additional revalidation is
required (with or without conﬁrmatory testing in
phase III).
4. Cognitive testing/debrieﬁng is required (with or
without conﬁrmatory testing in phase III).
The FDA’s position is somewhat unclear. The draft
guidance states both that “The extent of additional
validation recommended depends on the type of modi-
ﬁcation made” and that “The FDA intends to consider
a modiﬁed instrument as a different instrument from
the original and will consider measurement properties
to be version-speciﬁc” [1]. We believe the extent of
psychometric revalidation required depends on the
degree of modiﬁcations made and the research frame-
work used to support the validity of the modiﬁcation.
A novel PRO measurement strategy may require a
comprehensive psychometric program, including item
generation and reduction with patient input; deve-
lopment of scoring methods; and documentation of
validity, reliability, and responsiveness to change. Con-
versely, adaptations and modiﬁcations that represent
subtle changes in clinical context or setting but that
rely on a well-developed research framework should
not require a full psychometric validation. For
example, if a domain such as Vitality from the SF-36 is
part of a PRO measurement strategy, its psychometric
lineage should enable its use with minimal additional
validation. Similarly, if an instrument has not been
used in the target population but has been used in a
similar population (e.g., one cancer versus another), a
rationale describing how the two populations are sub-
stantially similar should sufﬁce, and additional valida-
tion work in the target population should not be
required.
Subsequent sections of this article address the
degree of validation we believe is appropriate for dif-
ferent types of modiﬁcations. We pay special attention
to highlighting circumstances in which we believe com-
prehensive revalidation is unnecessary. Before describ-
ing these recommendations, we explain below the key
considerations and guiding principles on which they
are based.
Need for Reasonable Pragmatism
Practical implications of revalidation requirements. In
setting forth recommendations on revalidation
requirements, we want to emphasize the practical
implications of the recommendations and the effects of
these implications on product labeling and promo-
tional claims. Because labeling is intended to provide
complete, accurate, and balanced information to
health-care practitioners, and because important clini-
cal decisions are made on the basis of the information,
the evidence requirements are deliberately rigorous.
On the one hand, setting the evidence threshold so
low that it compromises the accuracy or reliability of
the conclusions obtained would be detrimental, not
only to patients, but also to the credibility and value of
PRO research. On the other hand, setting the threshold
too high could also undermine both clinical decision-
making and PRO research. If the criteria are so
demanding that they are rarely met, sponsors may be
less likely to collect these data and, when they do, the
information will be less likely to reach health-care
practitioners. In either case, important PRO data
would be excluded from product labeling. For PRO
research to remain viable and attractive, practical
implications of guidelines and research recommenda-
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tions should be considered, and a balance sought
between the ideal and the practical.
Impact on conclusions regarding treatment effects.
With randomized clinical trials, most or all of the
changes in an instrument would be reﬂected equally in
treatment arms, thus such modiﬁcation cannot affect
the relative comparisons across arms. For example,
even though pain ratings have been shown to vary with
the orientation of the visual analog scale [24], such
changes would affect both treatment groups equally
and would not be expected to alter the study’s
conclusions.
Most decisions to assume the validity of a modiﬁca-
tion or adaptation based on the validity of the original
text version increase the risk of Type II error, or failure
to detect an effect that is actually there. Although this
effect is not ideal, in a regulatory approval context it
amounts to accumulation of sponsor risk rather than
any unfair or unique advantage.
With these guiding principles in mind, we discuss
the types of modiﬁcation and their revalidation
requirements below.
Types of Modiﬁcations
Change in wording or content. With continued use
of an instrument over time, opportunities arise to
improve its performance through relatively small
changes in the wording or content of items, response
options, or instructions. For example, with an instru-
ment that performs well in one language, the process
of developing translations may suggest further re-
ﬁnements to item wording in the original (source)
instrument. These changes typically enhance the
instrument’s properties and do not trigger a need for
complete revalidation. Thoughtful cognitive testing
and debrieﬁng with a small group of patients can
provide added conﬁdence that the modiﬁcations are
interpreted as intended.
When investigators select an established question-
naire, sponsors may wish to make changes that beneﬁt
other instruments. These steps can take the form of
reducing the number of response options to improve
reliability or expanding the number of responses to
improve responsiveness. For example, Version 2.0 of
the SF-36 improved on the previous version by substi-
tuting ﬁve-level response options both for the dicho-
tomous response options in some items and for the
six-level response options in other items [25]. The
probability is extremely high that other questionnaires
using the same set of six-level response options as the
earlier version of the SF-36 would beneﬁt from the
same revisions.
A PRO instrument may need to be updated to
reﬂect the effects of new treatments. For example, a
questionnaire or checklist designed to evaluate speciﬁc
side effects of treatments for a particular disease might
need to be expanded as new treatments emerge. In this
case, the modiﬁcation is necessary to ensure that
content validity is preserved.
Change in mode of administration. A recent issue is
how much revalidation is required when an instrument
originally developed for paper-and-pencil administra-
tion is modiﬁed for electronic administration. Elec-
tronic administration comprises both interactive voice
response systems (IVRS) and computer administration;
the form of the latter can vary considerably with the
speciﬁc device employed. The issues arising from a
change in the mode of administration, and the poten-
tial for this to inﬂuence the data collected, will there-
fore depend on the speciﬁc technology.
A key consideration with IVRS is the additional
memory load imposed on respondents when subjects
must remember the instructions, questions, and
response options. In contrast, if a standard-size com-
puter monitor is used, a computerized version of the
instrument could be constructed to mimic the paper
questionnaire in terms of its layout and other key
features. Portable electronic devices that are smaller in
size, may require changes to the layout of the ques-
tionnaire and may limit the amount of information
that is simultaneously available.
To conﬁrm that the psychometric properties of
an instrument are retained when a paper instrument
is modiﬁed for electronic administration, current
common practice is to undertake cognitive testing to
establish that subjects can navigate the electronic
version and to conduct a small study to conﬁrm that
the basic psychometric properties of the instrument are
unchanged. With additional experience in computer
administration, however, conducting even a small
validation study may no longer be necessary. After
comparing alternative forms of questionnaires for
measuring health-related quality of life and utilities,
Guyatt concluded that measurement properties are
“seldom affected” by changes in method of adminis-
tration [26]. As experience with electronic administra-
tion accumulates, researchers may be able to identify
the factors that determine when differences between
modes of administration will occur and to apply these
principles to facilitate construction of an electronic
version that will replicate the psychometric properties
of an original article version. Similarly, moving from
either computer or oral administration to paper
administration may or may not be relatively straight-
forward depending on the structure of the question-
naire. In particular, a potential advantage of electronic
administration, the use of complex skip patterns, may
be very difﬁcult or impossible to reconstruct on paper.
An ePRO Consensus Development Working Group
(details available at http://www.ISPOR.org) has been
convened to review the state of the science and develop
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recommendations for ensuring that PRO data quality
is maintained when researchers adapt paper instru-
ments to an electronic medium. Until those recommen-
dations are issued, at a minimum, researchers should
perform cognitive testing. A small validation study
may facilitate acceptance by the FDA, but at the
present time, we cannot make ﬁrm recommendations
about how investigators should proceed as they move
from paper to electronic media.
Translation and cultural adaptation. When investiga-
tors need to modify an instrument developed in one
language for other languages and/or cultures, the
FDA guidance suggests that sponsors use “generally
accepted” methods for translation and cultural adap-
tation and also that they provide evidence that the
measurement properties of the translated and cultur-
ally adapted versions are comparable [1]. Although the
general consensus seems to be that a rigorous transla-
tion and cultural adaptation process is important,
more than one method can be applied to accomplish
this step. Moreover, the incremental value of some
steps in the process continues to be debated. Ideally,
the psychometric properties of each translation and
cultural adaptation would be established before spon-
sors use them in phase III trials. Nevertheless, because
phase III trials are typically much larger than phase II
trials, they often include countries that had not been
included in phase II. In this case, if the translations and
cultural adaptations are not already available, a sepa-
rate study would need to be conducted to conﬁrm the
psychometric properties of those versions––a signiﬁ-
cant undertaking. Moreover, if enrollment to a phase
III study is not proceeding as planned, additional coun-
tries may be required to meet recruitment targets. If the
sponsor’s goal is to obtain evidence for a treatment
effect, then as explained above, translations and cul-
tural adaptations that fail to replicate the psychometric
properties of the original instrument may make detect-
ing an effect more difﬁcult; they are very unlikely to
confer an unfair advantage.
Application to a different patient population. A
related question is what amount of revalidation, if any,
is needed when an existing instrument is used without
revision in a patient population different from that for
which it had been originally developed and validated.
It is important to step back and reﬂect on the assump-
tion that a well-studied and validated instrument must
be revalidated in the target trial population. The posi-
tion supporting the need to revalidate an instrument in
new samples is grounded in unproven classical test
theory. Cases exist in which special considerations
should be made for new applications of validated
tools; however, a good generic instrument measuring
a common concept is valid when applied to people
across a wide variety of diseases. When a generic
measure has previously been demonstrated as valid
and reliable across diverse patient populations, exten-
sive revalidation in a new patient population should
not be required. Although equivalent measurement
across groups is not guaranteed, it can be tested a
posteriori. These possibilities should be considered
carefully when reviewing a proposed measurement
strategy, and a principle of reasonable pragmatism
should be included in the deliberation.
Applying a disease-speciﬁc instrument to a popula-
tion other than the one in which it was originally
developed and validated may not require any modiﬁ-
cation or may require only substituting the new disease
state for the original one in the question stem. If no
signiﬁcant content changes are needed, and the target
population is substantially similar to the population in
which the instrument was developed and validated,
additional validation work may be unnecessary. In this
case, investigators describe in detail the similarities
between the two populations. In other cases, the
content may need to be modiﬁed to make it more
appropriate to the target population. When changes
are made to tailor an existing questionnaire to a new
patient population, the level of revalidation required
will depend on the signiﬁcance of the modiﬁcations
made. For example, in the evaluation of abatacept for
RA, the research team developed an Activity Limita-
tion Questionnaire (ALQ) to assess the number of days
that patients were unable to perform usual activities
because of this condition. Because many RA patients
are female, of middle age (mean age, 55 years), and
unemployed, or because in international trial settings
many countries may have high unemployment rates,
work-speciﬁc questionnaires may not be appropriate.
Thus, for this particular study, the work-related ques-
tions in the ALQ were modiﬁed to use a more general
deﬁnition of usual activities that included work,
whether or not for pay, and any other activities the
patient does during the day. Because this modiﬁcation
was relatively minor, the revalidation required was
minimal.
Finally, disease-speciﬁc questionnaires developed
and validated with a sample that is representative of
the patient population will generally require no further
revalidation for use in subgroups delineated either by
demographic variables (e.g., race, sex) or by symptom
type or severity. Conversely, a questionnaire developed
speciﬁcally for a particular disease or demographic
subgroup cannot be assumed to retain its psycho-
metric properties when applied to a broader patient
population.
Conclusions
Using PRO data to support a labeling claim calls for
more than just instrument selection. A well-deﬁned
measurement strategy should be devised with careful
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attention paid to identiﬁcation of appropriate domains
to be measured, instrument(s) to utilize, and, if neces-
sary, revalidation requirements. The FDA require-
ments for use of PRO data in labeling claims should be
no more or less stringent than those used for other
clinical end points. As long as the PRO measure rep-
resents a valid concept that can be operationalized and
tested, conforms to the prespeciﬁed claim structure, is
supported by evidence from a prespeciﬁed statistical
plan, and is reported with fair balance, PROs should
be eligible to support claims of patient beneﬁt.
Looking to the future, the efﬁciency with which
PRO research is conducted could be improved by
further efforts to address the need for revalidation.
Steps to accomplish this include:
• Identifying empirically the boundaries within
which changes can be made without substantially
altering an instrument’s measurement properties.
There is a wealth of experts from whom to draw
consensus on this issue.
• Describing a set of principles to use in determining
when modiﬁcations can be expected to alter mea-
surement properties in such a way that the legiti-
macy of treatment comparisons is questionable.
• Conducting simulations to illustrate how changes
in the psychometric properties of instruments
would affect conclusions drawn from a trial.
At the present time, the basic principle of using the best
available measurement of an important concept should
prevail in any given decision.
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